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Abstract
Background: Congestive Heart Failure (CHF) is a serious cardiac condition that brings high risks of urgent
hospitalization and death. Remote monitoring systems are well-suited to managing patients suffering from CHF,
and can reduce deaths and re-hospitalizations, as shown by the literature, including multiple systematic reviews.
Methods: The monitoring system proposed in this paper aims at helping CHF stakeholders make appropriate
decisions in managing the disease and preventing cardiac events, such as decompensation, which can lead to
hospitalization or death. Monitoring activities are stratified into three layers: scheduled visits to a hospital following
up on a cardiac event, home monitoring visits by nurses, and patient’s self-monitoring performed at home using
specialized equipment. Appropriate hardware, desktop and mobile software applications were developed to enable
a patient’s monitoring by all stakeholders. For the first two layers, we designed and implemented a Decision
Support System (DSS) using machine learning (Random Forest algorithm) to predict the number of
decompensations per year and to assess the heart failure severity based on a variety of clinical data. For the third
layer, custom-designed sensors (the Blue Scale system) for electrocardiogram (EKG), pulse transit times, bio-
impedance and weight allowed frequent collection of CHF-related data in the comfort of the patient’s home.
We also performed a short-term Heart Rate Variability (HRV) analysis on electrocardiograms self-acquired by 15 healthy
volunteers and compared the obtained parameters with those of 15 CHF patients from PhysioNet’s PhysioBank archives.
Results: We report numerical performances of the DSS, calculated as multiclass accuracy, sensitivity and specificity
in a 10-fold cross-validation. The obtained average accuracies are: 71.9% in predicting the number of
decompensations and 81.3% in severity assessment. The most serious class in severity assessment is detected with
good sensitivity and specificity (0.87 / 0.95), while, in predicting decompensation, high specificity combined with
good sensitivity prevents false alarms. The HRV parameters extracted from the self-measured EKG using the Blue
Scale system of sensors are comparable with those reported in the literature about healthy people.
Conclusions: The performance of DSSs trained with new patients confirmed the results of previous work, and
emphasizes the strong correlation between some CHF markers, such as brain natriuretic peptide (BNP) and ejection
fraction (EF), with the outputs of interest. Comparing HRV parameters from healthy volunteers with HRV parameters
obtained from PhysioBank archives, we confirm the literature that considers the HRV a promising method for
distinguishing healthy from CHF patients.
Background
Congestive Heart Failure (CHF or HF) is a serious cardiac
condition that carries high risks of emergency hospitaliza-
tion and death. CHF is prevalent in the aging population,
as it affects 3-20 out of 1,000 adults and up to 10% of peo-
ple aged between 80 and 89. In the UK, CHF consumes
almost 2% of the National Health Service’s budget, most
of the cost being linked to hospital admissions [1].
Drug therapy is the mainstay of treatment for CHF.
However, management has evolved over the last several
years from a traditional model almost solely based on cri-
sis intervention towards more proactive and preventative
disease management models supported by a combination
of medications and preventive paradigms, including a
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healthy lifestyle. This management concept, defined as
Chronic Care Model (CCM) [2], aims at establishing the
pillars of a “medicine of initiative” in which the physician
takes action before the disease worsens, as opposed to
the old model of “waiting medicine” in which the patient
is treated when the disease is already in its acute phase.
The ultimate goal of CCM is to reduce re-hospitaliza-
tions that have negative effects on both the quality of life
of the patient and the national annual cost for treating
CHF. Therefore, identifying the causes that lead to CHF-
related re-hospitalization provides the opportunity to
redesign care to prevent re-hospitalization and subse-
quently to improve quality of life [3].
Building an effective disease management strategy
requires analyzing many variables, including the care
setting, the ability of the patient and family to perform
self-management and the severity of the disease [3]. A
Cochrane Collaboration review found that home moni-
toring (by telephone support and vital sign monitoring)
significantly reduces all causes of mortality in CHF
patients [4]. A more recent review by the Cochrane Col-
laboration [1] concluded that follow-up on CHF patients
through periodic telephone calls and home visits
resulted in fewer deaths from all CHF causes compared
to periodic, scheduled visits to a CHF specialist or hos-
pital or to multidisciplinary interventions carried out by
a team of professionals helping the transition from the
hospital to the home, although the study was not suffi-
ciently comprehensive to determine the best overall
strategy. In addition, current practice guidelines and
consensus statements on CHF, including the most
recent American College of Cardiology/American Heart
Failure guideline (2013), agree that CHF is a multifac-
torial disease that requires continuity of care outside the
hospital, including coordination of multiple health pro-
fessions and proactive self-management by the patient
[5].
However, the intrinsic complexity of proactive self-
management, mainly due to detailed and nuanced proto-
cols, is a significant cause for lack of adherence by
patients and their families, which in turn results in high
rates of unnecessary hospitalizations [6], [7]. Decision
support systems based on personalized, actionable
patient data can facilitate communication and collabora-
tion across care levels and therefore represent an impor-
tant advancement towards the solution of this issue. In
this work, we propose a solution consisting of a combi-
nation of custom-designed sensors for home measure-
ments with a three-layer monitoring model (two clinical
layers and one patient layer) that involves clinical stake-
holders assisted by two Decision Support Systems (DSS)
based on a powerful machine learning engine. Desktop
and mobile software tools complement the system by
offering a friendly interface for caregivers. The novelty
of this work compared to the state of the art is the applica-
tion of DSSs designed specifically for each clinical stake-
holder (nurses and physicians), together with the
monitoring model based on three layers that allows an
effective compromise between the quality of the moni-
tored parameters (and the possibility of acquiring para-
meters that are CHF markers) and their acquisition
frequency. In previous studies, we identified and imple-
mented the appropriate machine learning technique for
dealing with the CHF. In this work, we retrained the sys-
tem with larger, more structured datasets in order to
improve prediction performances and the statistical valid-
ity of the results. Another innovative aspect of this work is
the integration of several independent modules (DSSs,
sensor devices for patient homecare, telemedicine infra-
structures, cross-platform interfaces) into a single system
generating new workflows that will allow stakeholders at




The system described in this paper aims to help CHF
stakeholders (families, patients, and caregivers at all
levels) make appropriate CHF management decisions
through a three-layer monitoring system (which partly
reflects the solution described in [1]) consisting of two
clinical layers (Layers 1 and 2) and one patient layer
(Layer 3). The system relies on the concept of collabora-
tive framework and is based on an HIPAA-compliant
cloud architecture that allows centralized collection and
secure sharing of information among different layers
and stakeholders (see Figure 1). In this context, clinical
stakeholders in the upper two layers are provided with a
Decision Support System (DSS) geared to specific
aspects of CHF, whereas Layer 3 is currently focused on
data collection in the patient’s home. In this work, we
integrated CHF special-purpose modules which were
tested in our previous work [8] with other modules
appositely designed for testing the proposed monitoring
and decision support system as a whole. When com-
pared to individual modules taken separately, our pro-
posed solution results in information and decision
support being provided to stakeholders in a more multi-
factorial and multi-parametric manner, while reducing
the time needed for patient evaluation and the cost of
both false positives (unnecessary hospital readmissions)
and false negatives (missed necessary readmissions).
Based on a collaborative investigation involving expert
clinicians that modeled the time progression of CHF, we
proposed a system including several types of monitoring
scenarios differing by the number of clinical measures and
their sampling frequency [9]. Specifically, we designed a
multi-layer monitoring structure in which a set of
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measured clinical parameters were weighted with inverse
proportion to the frequency with which they are acquired,
so as to establish a reasonable trade-off between the num-
ber of useful clinical data points and the burden and cost
of collecting them.
The most comprehensive, yet least frequent, monitoring
layer (Layer 1) consists of a complete scheduled cardiac
outpatient visit to be performed in a hospital or at another
point of care. In addition to a thorough physical exam and
collection of medical history, this visit allows the recording
of all clinical measures known to be relevant to CHF,
including those that vary slowly over the progression of
the disease such as ejection fraction (EF) and Brain
Natriuretic Peptide (BNP). Pharmaceutical therapy is also
prescribed as the doctor sees fit. This layer is characterized
by an acquisition rate of clinical parameters of about 6
months, corresponding to the frequency of the compre-
hensive visit. Through a dedicated desktop application
described in [10], the specialist can keep the clinical status
of the patient up to date with newly acquired parameters,
therapy, medical history and model-based prognosis
scores, all of which are stored into a database shared
across all layers of the proposed system.
The second layer of monitoring (Layer 2) in order of
acquisition frequency (every 1-2 weeks) is performed by a
nurse visiting the patient at home using a measuring kit
coupled with a tablet computer. A dedicated app
(described in the section below) allows the nurse to enter
all relevant measures (i.e., clinical parameters and ques-
tionnaires) that are subsequently stored into the shared
database system.
While Layers 1 and 2 described above are designed
around caregivers (doctor and nurses, respectively) who
are expert in CHF, Layer 3 is entirely patient-oriented. In
this layer, the CHF patient is entrusted with the responsi-
bility of contributing to his/her own care by actively enga-
ging in disease self-management, as proposed in the CCM
model [2]. To achieve this, monitoring in Layer 3 consists
of a frequent data acquisition (1-2 times/day) of several
CHF-related parameters such as electrocardiogram (EKG),
heart rate (HR), pulse transit times (PTT), weight and
bioimpedance (bioZ) performed at home using custom-
designed monitoring devices and shared across layers.
In this framework, no layer of the system operates inde-
pendently from the other layers. At the first hospitalization
for acute symptoms of CHF or on the first scheduled visit
for evaluation of chronic symptoms, patients are enrolled
in the various layers of monitoring depending on a calcu-
lated score that accounts for relevant indicators (e.g., age,
comorbidities, number of past hospitalizations for heart
disease, etc.), clinical data (BNP, EF, renal functions, etc.),
as well as historical data and symptoms-based NYHA
Figure 1 Monitoring Schema and respective stakeholders.
Guidi et al. BMC Medical Informatics and Decision Making 2015, 15(Suppl 3):S5
http://www.biomedcentral.com/1472-6947/15/S3/S5
Page 3 of 14
class [11]. This type of multi-layer monitoring leads to
hierarchically structured time-dependent data; hence, an
hypothetical patient who is under monitoring in all three
layers will be exhaustively checked every 6 months in the
hospital (collecting BNP, EF, 12-lead EKG, laboratory data,
etc.), every 2 weeks by a nurse visit at home (consisting of
physical examination and collecting capillary BNP data)
and on a daily basis through self-measurements (weight,
2-lead EKG, PTT, bioZ). Figure 2 shows that such a com-
plex system represents an effective tradeoff between the
measurement frequency and the number and relevance of
the parameters, since strong CHF markers (as found in
[8]) require blood (BNP) or ultrasound (HF) testing that
cannot be easily performed at home.
Monitoring layers
Layer 1: Scheduled follow-up in clinic or hospital
The first layer of the proposed system provides the phy-
sician with a desktop application (previously described
in [10]) with the following functions:
• Serves as a management software including CHF-
specific computational and graphical tools for calcu-
lation of prognostic scores, smart management of
therapy, display of various CHF-related parameters;
• Serves as an input portal for training of the machine-
learning tool (DSS) used in Layer 2 (nurse visits);
• Displays management suggestions provided by the
DSS underlying Layer 1;
• Acts as a control and display panel for Layer 3,
self-monitoring performed autonomously by the
patient at home.
The clinical parameters obtained and entered into the
system by the physician in Layer 1 are:
• Height and weight (Body Mass Index)
• Systolic and diastolic blood pressure
• Heart rate
• Oxygen saturation
• Ejection fraction (EF)
• BNP or NT-proBNP
• Bioelectrical impedance vector (BIVA) parameters
• NYHA class
• 12-lead EKG report (e.g., presence of bundle
branch block, tachycardia, atrial fibrillation, etc.)
• Etiology
• Comorbidity
• Current therapy, pharmaceutical and surgical
(pacemaker or ICD ICD / CRT)
Previously released guidelines [5] indicate that Cardiac
Troponin is an additional significant biomarker of CHF,
although it is a more direct marker of myocardial infarc-
tion and acute coronary syndrome. However, we chose
to include only one blood marker (BNP) that could be
measured with portable point of care devices to mini-
mize the cost of each measurement.
In this layer, prognostic scores such as 1-year and 5-
year survival rates are calculated from patient-specific
data using accepted models [10]. Layer 1’s DSS provides
the physician with a forecast of frequency of patient
decompensation events to be expected during the subse-
quent year (e.g., none, 1-2 exacerbations, >2 exacerba-
tions) using the predictive model described in [8].
Figure 2 The layers of monitoring: compromise between the follow-up frequency and the prognostic strength of the measured
parameters.
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Layer 2: Home monitoring by nurse
In this layer, data collection and monitoring is periodi-
cally performed by a nurse visiting the patient at home
equipped with a set of portable devices. The measure-
ment protocol includes:
• Examination of qualitative parameters (jugular turgor,
skin color, ankle edema, pressure ulcer);
• Acquisition of vital signs: Weight, blood pressure,
oxygen saturation, bioimpedance using portable instru-
ment, capillary dosage of BNP using portable device.
To achieve time- and cost-effective monitoring, we
designed an Android mobile application for tablets and
smartphones that enables data collection and transmission
to the shared database, so that data acquired at point of
care are also immediately available to the cardiologist.
Since it is impractical for the cardiologist to check clinical
data on a daily basis, we trained the DSS in this monitor-
ing layer to provide a stratification of the severity of the
patient’s condition in three levels (mild, moderate, severe)
so to enable a closer follow-up on patients with higher
risks of decompensation. Such classification is based on
machine learning techniques described in [12] that take
into account a multi-parametric description of the patient,
rather than a threshold-based analysis of individual clinical
measures. By mean of this app, the nurse is immediately
alerted to the severity assessment of the patient’s CHF and
its variance from previous readings. A representative
screenshot of the app used on a 10-inch tablet is shown in
Figure 3.
Layer 3: Patient self-monitoring using measurement kit
In this monitoring layer, portable devices are provided to
the patient for acquiring daily measurements of several
physiological measures relevant to CHF. After collection,
data are securely transmitted and stored in the HIPAA-
compliant central database for immediate consultation
and processing. Depending on the recommendation of the
physician and the usage preference of the patient, the
monitoring within Layer 3 will be performed choosing
between devices with different form factors.
One option is represented by a handheld device called
BlueBox that integrates two sets of electrodes (left hand
and right hand) for collecting 2-lead electrocardiography
(EKG) and bio-impedance signals [13]. In addition, it
embeds a photoplethysmography sensor (PPG) for the
measurement of the pulse transit time (PTT), that is, the
time interval between the cardiac contraction (EKG’s
R-wave) and the arrival of the blood wave to the periph-
ery, i.e., the fingertip (Figure 4). PTT is a cardiovascular
measure that has been shown to be related to arterial
stiffness [14]. Recently, our group has also found that
PTT is a valuable addition to heart rate as a surrogate of
cardiac output, oxygen uptake and stroke volume during
Figure 3 Android app to enable nurses to acquire the parameters in the patient’s home.
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physical exercise [15]. Hence, PTT has the potential to
provide additional quantitative information on the cardi-
ovascular system without using measurement tools that
are invasive or are available only in clinical settings. Blue-
Box communicates with the user by means of a small dis-
play and securely transmits the data to the central
database using a Bluetooth gateway.
Surveys conducted on BlueBox users revealed that the
majority of elderly CHF patients did not acquire a suffi-
cient familiarity with the handheld device and would
have preferred to deal with a tool that better fits their
lifestyles. Hence, a second-generation device called Blue-
Scale was conceived around a familiar household tool
frequently used for CHF management: a bathroom scale.
To expand the measurement capabilities of BlueBox and
to meet this identified need, we modified a bathroom
scale to integrate foot electrodes and attached a metal
assembly consisting of a horizontal handlebar and a ver-
tical post [16] integrating a pair of hand electrodes (one
per hand), a finger-clipping PPG sensor and a large
touchscreen display (Figure 5). In comparison to Blue-
Box, the improved design of BlueScale allowed the col-
lection of a 3-lead EKG (left hand-right hand-left foot),
whole-body bioimpedance and also weight, deviations in
which over time are relevant to CHF. Data collected by
BlueScale are transmitted to the central database via
secure WiFi. Upon a preliminary adherence study, we
found that this form factor was better adopted by the
population of potential users [17].
In our proposed workflow model, decision-making is a
responsibility that resides entirely with the caregivers and
never relies on the patient’s ability to interpret complex
mechanisms and results. Since Layer 3 was designed solely
to collect relevant data with high sampling frequency for
upper layers where clinical decisions are made, this layer
did not include any specific DSS.
Cardiologist Dashboard
An important feature of the proposed system is the
dashboard that collects and manages all the data incom-
ing from the monitoring layers. The dashboard is inte-
grated as a plug-in to the same experimental interface
provided to the doctor for ambulatory follow-up moni-
toring (see Figure 6 and 7).
As can be seen in Figure 6, the cardiologist, after
selecting a patient from the list, can access the man-
agement section of the ambulatory follow-up and can
either enter data newly acquired in the hospital
(Layer 1), or can display data coming from Layers
2 and 3 of monitoring (nurse or self-monitoring). In
particular, Figure 7 shows the panel displaying data
self-collected by the patient in addition to EKG-related
parameters computed using the Heart Rate Variability
Analysis Software tool (HRVAS) [18]. Studies show
that HRV parameters are highly correlated with the
severity of CHF and thus may be used as features to
train machine learning algorithms aimed at predicting
CHF decompensation [19,20]. Prior to display, the EKG
waveform is processed using wavelet decomposition to
eliminate some artifacts and to obtain a stable baseline
(eliminating the effects of breathing and other fluctua-
tions), whereas QRS complexes are detected using a
template matching method.
Experimental setup
The DSSs implemented in Layers 1 and 2 were trained
and evaluated using internal anonymized datasets whereas
publicly available CHF data (i.e., PhysioBank) and data
Figure 4 Blue Box Device.
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acquired on healthy volunteers were used to evaluate the
performance of Layer 3.
Unlike our previous work (see the results in [8]) where
sparse, longitudinal datasets were used, we hereby uti-
lized a cross-sectional dataset consisting of first-visit data
of 250 patients. For DSS validation purposes, each record
was retrospectively labeled by a cardiologist as:
a. None, rare or frequent according to the number of
times the patient was hospitalized for CHF aggravation
in the year after such first visit, corresponding respec-
tively to never, <= 2 times, > 2 times
b. Mild, moderate, or severe according to the clinician’s
evaluation of the CHF status
After proper training, the DSS for Layer 1 should pre-
dict the frequency of CHF aggravation, whereas DSS for
Layer 2 should automatically classify the severity of
CHF using only clinical data collected during the
patient’s first visit.
Since subsets of clinical data were missing on some
patients, not every numeric input could be used for train-
ing. Hence, we chose to test the DSS performance using
the following 8 parameters, which were available for all
250 patients: systolic blood pressure (SBP), diastolic blood
pressure (DBP), heart rate (HR), weight, BNP, ejection
fraction (EF), gender, age. Table 1 summarizes the classifi-
cation operated by the cardiologist based on his or her
expertise.
Figure 5 Blue Scale Device.
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Figure 6 Cardiologist Dashboard - main.
Figure 7 Cardiologist Dashboard - Patient self-monitoring view.
Table 1 Dataset distribution.
Type of output N° of patients in Class 1 N° of patients in Class 2 N° of patients in Class 3 Sum
CHF Severity
(mild/moderate/severe)
93 92 65 250
CHF decompensation
(none/rare/frequent)
161 55 64 250
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Both DSSs for Layer 1 and Layer 2 were based on Ran-
dom Forest [21], i.e., the machine learning technique that
yielded the best results in our previous study [22] and in
other classification-tree-based approaches [23]. In this
work, we maintained the internal parameters of the Ran-
dom Forest used previously [22] in order to test the ability
of such a setting to perform on a different dataset. The
parameters used in this study were:
• Number of trees in the forest = 2000, determined by
evaluating the reduction of Out of Bag error by
increasing the number of trees;
• Number of features to be used in each tree = 4,
empirically determined in cross-validation in [22];
• Cut-off for each class was set in order to take into
account the imbalance of the dataset. For CHF severity
output it was (class 1:30 / class 2: 30 / class 3: 40) and
for CHF decompensation (class 1: 50 / class 2: 20 /
class 3: 30). Given that a low cut-off makes a class an
“easy-winner” and observing Table 1, we see that these
values are theoretically valid also for the new dataset.
However, while as regards the severity assessment,
these values are confirmed, with regard to the predic-
tion of decompensation event, in this work we used a
70-15-15 configuration that takes into account the
even more strong imbalance of the new dataset, in
order to maximize the specificity of class 1 (have really
no decompensation, either rare or frequent, if the sys-
tem predicts “none”). This configuration was per-
formed by observing the classes distribution in Table 1.
A meaningful internal parameter of the Random For-
est training process is the mean decrease of the Gini
impurity index, providing information on the impor-
tance that each input has on the prediction of the out-
put value. In fact, the Gini impurity index is a measure
of how often a randomly chosen element from the set
would be incorrectly labeled if it were randomly labeled
according to the distribution of labels in the subset.
Breiman, the father of the Random Forest algorithm
[21], proposed to evaluate the importance of a variable
× for predicting Y in each tree of the forest by adding
up the weighted impurity decreases and, in the most
common implementations, the Gini impurity index was
used. We used this index to evaluate whether our results
reflect the known literature about CHF-marker
parameters.
Data evaluation and statistical analysis
To evaluate the performance of the DSS in Layers 1 and
2, we used a 10-fold cross-validation method. Since each
DSS provided a three-class output, classification accu-





TPi + TNi + FPi + FNi
N
where TP, TN were the number of true positives and
negatives, respectively, and FP, FN were the number of
false positives and negatives, respectively, for each class.
In addition, we evaluated sensitivity and specificity of
the three-way classification using the method “one class
versus all the others”, i.e., sensitivity and specificity were
computed as in a binary classification predicting “severe
vs. mild + moderate”, “mild vs. moderate + severe” and
“moderate vs. mild+severe”. Classification and cross-vali-
dation using Random Forest were implemented in
Matlab (The Mathworks, Natick, MA) with both home-
made and GPLv3 license functions. We reported indivi-
dual-fold and average results, as well as the number of
critical errors, defined as cases in which a patient who
had no decompensation (class none) or was in severity
class mild was wrongly classified as one with frequent
decompensation or as a severe CHF (critical error 1-3).
Vice versa, critical errors 3-1 were defined as cases in
which frequent decompensation or severe CHF were
erroneously classified as none or mild, respectively.
For this study, data collected with self-monitoring
devices (BlueBox and BlueScale) were available only on
healthy patients [17]. However, we preliminarily assessed
the potential of EKG-derived parameters to disambigu-
ate healthy people from CHF patients using datasets
freely available in literature. Specifically, we performed
an analysis of short-term heart rate variability (HRV)
using the HRV toolkit from PhysioNet [24] on 15 healthy
patients with BlueScale in comparison to 15 CHF data-
sets obtained from PhysioBank. The HRV parameters
yield by the toolkit were AVNN (average of all normal
sinus to normal sinus (NN) intervals), SDNN (standard
deviation of all NN intervals), RMSSD (square root of
the mean of the sum of the squares of differences
between adjacent NN intervals), pNN20, pNN50 (per-
centage of differences between adjacent NN intervals
greater than 20 or 50 ms, respectively), TOTPWR (total
spectral power of all NN intervals 0-0.4 Hz). All HRV
parameters were measured in ms, except TOTPWR
which was measured in ms2. Short-term HRV was per-
formed on both cohorts after removing outlying data,
following the guidelines provided with the analysis
toolkit. Differences between healthy and CHF groups for
all HRV parameters were statistically tested with
Student’s t-test with a significance level set at p = 0.05.
Experimental protocol and informed consent form were
approved by the Institutional Review Board of participating
institutions. Participant gave informant consent before
being enrolled.
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Results
Layer 1
The aim of the DSS in Layer 1 was to make a prediction
of the frequency of CHF decompensation during the
year after the first visit based on the snapshot of data
available at such first visit. Table 2 shows the 10-fold
cross-validation accuracy, sensitivity and specificity for
one of the three classes (none, rare or frequent) evalu-
ated against the other classes, repeated for all combina-
tions of classes. Since there were no patients of class
frequent in the seventh fold, the corresponding sensitiv-
ity was not indicated. On average, the accuracy of the
classification was 72 ± 5 % (mean ± STD), whereas the
average sensitivity and specificity computed across all
comparisons were 60 ± 4 % and 78 ± 18 %, respectively.
The table also reports the number of critical errors
1-3 (i.e., the DSS classified the patient as none instead of
frequent) and of critical errors 3-1 (i.e., the DSS classi-
fied the patient as frequent instead of none). Out of
250 patients and cumulatively over the 10-fold valida-
tion, there were only 3 critical errors of type 1-3 and
2 critical errors of type 3-1. Figure 8 shows the mean
decrease of the Gini index across the 8 selected features
(SBP, DBP, HR, Weight, BNP, EF, Gender, Age), where
BNP was found to be the strongest predictor.
Layer 2
The aim of the DSS in Layer 2 was to classify the sever-
ity of the CHF condition as mild, moderate or severe
based on data available to nurses performing home visits
to the CHF patient. Similarly to the DSS of Layer 1, we
evaluated the performance in this layer in terms of mul-
ticlass accuracy, sensitivity, specificity for each class vs
all other classes, critical errors 1-3 and 3-1 obtained
with a 10-fold cross-validation (Table 3). Notably, the
average classification accuracy was 81 ± 7 % (mean ±
STD), with no errors of type 1-3 and only one error of type
3-1 (CHF erroneously classified as severe instead of mild),
whereas the sensitivity and specificity were 76 ± 10 % and
86 ± 7 %, respectively. Figure 9 shows the mean decrease
in Gini index of the Random Forest algorithm for Layer 2,
evidencing the greater sensitivity of the classifier to BNP
over other features.
Layer 3
HRV parameters computed using the PhysioNet HRV
Toolkit on 15 healthy and 15 CHF patients are reported in
Table 4. Upon statistical comparison, we found that
SDNN, RMSSD and pNN20 were strongly different (p <
0.0001) amongst CHF and healthy groups, whereas
pNN50 exhibited a milder yet significant difference (p <
0.01). AVNN and TOTPWR were not found to be statisti-
cally different.
Discussion
Monitoring CHF patients outside of clinical settings is
known to be beneficial, primarily to reduce unnecessary
readmissions [1-4]. However, adequate monitoring of
CHF is not trivial due to the multifactorial nature of the
disease. The distributed system proposed in this work
aims at capturing multiple aspects of CHF by promoting
cooperation among clinical stakeholders operating in
three layers (physicians, nurses, patients) and by opti-
mizing the trade-off between quality and quantity of
acquired clinical data.
One innovative element of the proposed system is the
integration of decision support systems (DSSs) appo-
sitely designed for Layers 1 (physician level) and 2
(nurse level) to facilitate development and implementa-
tion of personalized, accurate and informed strategies to
maximize the outcome on each patient. Performances of
DSS at both levels estimated with a 10-fold validation
on a dataset of 250 CHF patients were particularly pro-
mising. The Random Forest algorithms were primarily
Table 2 performances of DSS of layer 1.
Fold N° Accuracy % N° critical error 1-3 N° critical error 3-1 “None” vs all “Rare” vs all “Frequent” vs all
Sens Spec Sens Spec Sens Spec
1 73.3 0 0 0.55 0.93 0.89 0.44 0.20 1
2 77.8 0 0 0.50 1 1 0.61 1 1
3 69.2 0 0 0.56 0.75 0.50 0.55 0.50 1
4 77.8 0 1 0.64 1 1 0.68 0.60 0.94
5 73.3 0 0 0.60 0.70 0.33 0.71 1 0.94
6 69.2 1 0 0.69 0.62 0.33 0.71 0.50 0.91
7 69.1 0 0 0.55 0.63 0.50 0.55 - 0.96
8 77.8 0 1 0.64 1 0.83 0.67 0.50 0.94
9 63.9 1 0 0.44 0.50 0.50 0.50 0.50 1
10 67.9 1 0 0.50 0.78 0.60 0.55 0.50 0.96
Average 71.9 3 (sum) 2 (sum) 0.57 0.79 0.65 0.60 0.59 0.96
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Figure 8 Strong correlation between BNP (feature 5) and prediction of decompensation.
Table 3 performances of DSS of layer 2.
Fold N° Accuracy % N° critical error 1-3 N° critical error 3-1 “Mild” vs all “Moderate” vs all “Severe” vs all
Sens Spec Sens Spec Sens Spec
1 81.3 0 1 0.6 1 0.8 0.73 0.7 0.8
2 71.4 0 0 0.3 1 0.83 0.47 0.8 0.9
3 79.5 0 0 0.46 1 1 0.64 0.89 1
4 77.8 0 0 0.86 0.71 0.17 0.87 0.88 0.92
5 90.0 0 0 0.83 0.93 0.88 0.83 0.83 1
6 94.9 0 0 1 0.93 0.71 1 1 0.95
7 73.8 0 0 0.88 0.50 0.33 0.92 1 1
8 83.8 0 0 0.92 0.80 0.67 0.81 0.63 1
9 80.6 0 0 0.64 0.80 0.75 0.69 1 1
10 80.3 0 0 1 0.73 0.53 1 1 0.91
Average 81.3 0 1 (sum) 0.75 0.84 0.67 0.80 0.87 0.95
Figure 9 Strong correlation between BNP (feature 5, capillary measurement) and EF (feature 6) with severity assessment.
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designed to minimize the number of critical errors, parti-
cularly those of type 1-3 where DSS erroneously classifies
the patient as stable instead of prone to frequent cardiac
decompensations. The validation has returned only
3 errors of type 1-3 out of 64 patients with actual frequent
decompensation (Layer 1), whereas the average accuracy
in predicting decompensations was a promising 71.9% for
a three-class classifier. Importantly, the specificity of classi-
fication into frequent decompensation (class 3) was quite
high (96%), indicating the likelihood of the patient
presenting frequent exacerbations in the future, whereas
the specificity for class 1 (no decompensations) was found
to be 79%. These results, largely driven by the strong cor-
relation between BNP (feature 5) and decompensation
events (as the Gini index in Figure 8 shows), hold potential
to prevent unnecessary close monitoring of patients who
are effectively managing their CHF.
DSS for Layer 2 also exhibited a good multiclass accu-
racy (81.3%) paired with high values of sensitivity (87%)
and specificity (95%) obtained for class 3 (severe CHF).
These results are clinically important, because they allow
the nurse to identify at-risk patients with a high degree of
confidence. The absence of critical errors of type 1-3 and
only one of type 3-1 are also of relevance. Class 1 (mild
CHF) was identified with good specificity (84%). In this
layer, Gini Index in Figure 9 shows that the most relevant
clinical parameters determining the severity of CHF are
BNP (feature 5) and EF (feature 6). Hence, our results at
both layers confirm previous findings that underscored
BNP as a strong indicator of CHF [5].
At Layer 3, HRV analysis revealed that healthy patients
exhibited measures comparable to large groups of healthy
people previously reported [25,26]. In particular, we
found that SDNN, RMSSD, pNN20 and pNN50 obtained
from short-term EKG were significantly different
between the groups (p < 0.001 or lower), which confirm
previous findings on the validity of these parameters for
disambiguating CHF patients from healthy controls [23].
Many artificial intelligence studies aiming at predicting
the severity of CHF or the onset of deterioration have
been reported using a wide variety of inputs and outputs,
making a direct comparison of performances difficult.
Few of these were based on machine learning techniques
using HRV computed from EKG signals, similarly to the
analysis performed in this work at Layer 3 [19,20,27].
Our proposed system includes novel elements in work-
flow modelling, management software (physician’s front
end), tele-monitoring and machine learning, and it
yielded EKG accuracy, sensitivity and specificity results
comparable with other systems [12]. Compared to a pre-
vious version of our solution described in [8,22], the
results of this study showed a similar accuracy (~80%)
using a larger dataset, which is particularly promising.
Yet, several issues must be resolved before further clini-
cal testing and potential adoption in clinical settings. Most
importantly, this system relies on the active participation
of all CHF stakeholders and, although our proposed solu-
tion facilitates such collaboration in different aspects, it
does not prescind from human willingness to engage in
management that is inherently complex. Other important
aspects are represented by the technical stability of the
architecture and the performance of the DSSs. This archi-
tectural stability encompasses issues such as data security
(both as privacy and protection against loss of data), relia-
bility and computational optimization of software, and cer-
tification of DSSs and medical devices. This research work
shows that our prototype system works well in a small-
scale simulated scenario. Our future plans include improv-
ing the performance of the DSSs, especially in predicting
decompensations (Layer 1), by enlarging training datasets
and including additional markers of CHF reported in the
literature to reflect states of inflammation, oxidative stress,
neurohormonal disarray or renal injury. However, we will
properly evaluate how measuring additional markers will
affect the workflow, cost, and trade-off between the prog-
nostic power of the clinical measures and the ability of the
system to monitor them frequently. Also, we will continue
to investigate both the importance of a properly trained
medical staff and the role of the patient and his/her ability
to effectively perform self-management at home by con-
sidering training and factors affecting adherence to the
protocols.
Conclusion
In this paper, we proposed a collaborative system for the
comprehensive care of congestive heart failure, beginning
in the hospital at the first admission (or first diagnosis
made during an office visit) and continuing through home
monitoring. This approach is in line with the increasingly
popular Chronic Care Model.
The proposed system consists of three layers of moni-
toring: Layer 1 in the hospital or cardiologist’s office,
Layer 2 with nurses vising the patient at home, and Layer
3 with self-monitoring by the patient. The prognostic
value of the CHF parameters measured at each level
Table 4 HRV parameters computed from
electrocardiogram signals collected in layer 3 on healthy
and CHF patients.
HRV parameter Healthy (N = 15) CHF (N = 15)
AVNN 675.75 ± 115.12 642.76 ± 119.21**
SDNN 68.89 ± 9.54 21.58 ± 7.59 ***
RMSSD 40.53 ± 8.12 20.36 ± 7.56 ***
pNN20 27.86 ± 5.41 9.77 ± 7.06 ***
pNN50 4.09 ± 1.12 2.39 ± 1.79 *
TOT PWR 282.84 ± 96.15 338.87 ± 142.12**
* p < 0.01, ** p < 0.001, *** p < 0.0001
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decreases from Layer 1 to Layer 3, but the measurement
frequency increases to establish a paradigm in which the
patient is constantly monitored. Since CHF is a multi-
parametric and multifactorial disease, all available infor-
mation collected at all layers is accounted for in auto-
mated decision support systems (DSSs) based on
machine learning techniques, and is easily accessible by
all stakeholders to facilitate decision-making. The perfor-
mance of DSSs trained with first-visit datasets showed
promising accuracy, sensitivity and specificity of CHF
classification in three classes (Layer 1: absent, rare, fre-
quent decompensation; Layer 2: mild, moderate, severe
CHF) and confirmed results of our previous work. We
found strong correlation between CHF markers (BNP
and EF) and disease severity and frequency of decompen-
sation, which confirm literature findings. We also found
that heart rate variability (HRV) computed on EKG self-
acquired by patients with devices for home monitoring
were significantly different in CHF and healthy cohorts.
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